Pomerantz Law Firm Investigates EyePoint, Inc. Following Clinical Trial Failures
Pomerantz LLP has launched an investigation into EyePoint, Inc. (NASDAQ: EYPT) regarding potential securities fraud or unlawful business practices. The probe follows two significant clinical setbacks for the company's lead product candidate, DURAVYU™ (vorolanib intravitreal insert), intended to treat wet age-related macular degeneration (wet AMD). In August 2026, EyePoint reported that its LUGANO Phase 3 trial failed to meet visual acuity benchmarks against Regeneron Pharmaceuticals' Eylea, causing a nearly 67% drop in share price. A subsequent failure in the LUCIA Phase 3 trial in October 2026 led to an additional 85% collapse in stock value. Consequently, EyePoint has terminated its wet AMD clinical program and implemented a 53% workforce reduction to pivot toward diabetic macular edema programs.
Coverage
- Pomerantz Law Firm Investigates Mueller Industries Following Third Quarter Earnings Miss
- Pomerantz Law Firm Investigates Potential Securities Fraud at Erasca, Inc.
- Pomerantz Law Firm Investigates EyePoint, Inc. Following Clinical Trial Failures
- Pomerantz Law Firm Investigates argenx SE Following Discontinuation of Phase 3 Sjögren's Disease Study
- Pomerantz Law Firm Investigates Syndax Pharmaceuticals Following Failed Phase 2 Clinical Trial
- Pomerantz Law Firm Investigates FreightCar America Following Backlog Cancellation and Guidance Cut
- Pomerantz Law Firm Investigates Evolus, Inc. Following FDA Warning Regarding Jeuveau Marketing
- Nu Skin Reports Third Quarter Earnings Miss and Lowers Future Guidance
- Gildan Activewear Lowers FY26 Outlook Following Third Quarter Earnings Miss